The antiplatelet agent ticagrelor has recently been found to have bactericidal activity, demonstrated in vitro and in an in vivo mouse model, which warrants further clinical investigations. The aim of this study was to evaluate infectious complications after coronary artery bypass grafting in patients pre-operatively treated with ticagrelor or clopidogrel. In a multi-centre trial, all adult patients who were pre-operatively treated with ticagrelor or clopidogrel prior to isolated primary coronary artery bypass grafting were eligible. Propensity score matching was used. Outcome measures were any sternal wound infection, deep sternal wound infection, and any in-hospital use of postoperative antibiotics. Of 2311 patients who were included, 1293 (55.9%) received clopidogrel and 1018 (44.1%) ticagrelor pre-operatively. In both overall and propensity score matched analyses, ticagrelor was associated with a similar incidence of infectious complications compared to clopidogrel. Our findings do not support a clinically relevant bactericidal effect of ticagrelor in patients undergoing coronary artery bypass grafting.

中文翻译：

---

冠状动脉搭桥术前接受替卡格雷或氯吡格雷的患者的感染并发症。

最近发现抗血小板药替卡格雷具有体外和体内小鼠模型的杀菌活性，值得进一步的临床研究。这项研究的目的是评估术前接受替卡格雷或氯吡格雷治疗的患者冠状动脉搭桥术后的感染并发症。在一项多中心试验中，所有在单独的冠状动脉搭桥术前接受替卡格雷或氯吡格雷术前治疗的成年患者均符合条件。使用倾向得分匹配。结果是胸骨伤口感染，胸骨深部伤口感染以及医院内使用术后抗生素。在纳入的2311名患者中，术前接受氯吡格雷的患者有1293名（55.9％），接受替格格雷的患者有1018名（44.1％）。在总体得分和倾向得分匹配的分析中，与氯吡格雷相比，替卡格雷与感染并发症的发生率相似。我们的发现不支持替卡格雷在接受冠状动脉搭桥术的患者中的临床相关杀菌作用。